At the November 2022 Obesity Week in San Diego, it was clear something big was happening. A late-breaking session released results of the STEP TEENS phase IIIa trial, showing 16 percent weight loss in adolescents with obesity treated with once-weekly semaglutide (Wegovy) for 68 weeks. The side effects were manageable and similar to those experienced
Many kids benefit from GLP-1s. What happens when they have to stop taking them? originally appeared in KevinMD.com.
